Cargando…
Perspectives for immune plasma treatment of COVID-19
BACKGROUND/AIM: The SARS-CoV-2 infection was declared as a pandemic by the World Health Organization (WHO) on March 11, 2020, and the death toll from COVID-19, which is the disease caused by SARS-CoV-2, has already surpassed that of many previous epidemics. A wide variety of treatment options are be...
Autores principales: | SAYINALP, Başak, ÇINAR, Olgu Erkin, HAZNEDAROĞLU, İbrahim Celalettin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Scientific and Technological Research Council of Turkey
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7991854/ https://www.ncbi.nlm.nih.gov/pubmed/32718128 http://dx.doi.org/10.3906/sag-2005-410 |
Ejemplares similares
-
Convalescent (immune) plasma treatment in a myelodysplastic COVID-19 patient with disseminated tuberculosis
por: Çınar, Olgu Erkin, et al.
Publicado: (2020) -
Comment on Zamfir et al. Hematologic Malignancies Diagnosed in the Context of the mRNA COVID-19 Vaccination Campaign: A Report of Two Cases. Medicina 2022, 58, 874
por: Çınar, Olgu Erkin, et al.
Publicado: (2022) -
The clinical course of COVID-19 in hematopoietic stem cell transplantation (HSCT) recipients
por: KARATAŞ, Ayşe, et al.
Publicado: (2021) -
Efficacy of eltrombopag in thrombocytopenia after hematopoietic stem cell transplantation
por: KARATAŞ, Ayşe, et al.
Publicado: (2022) -
Prolonged viral shedding in a lymphoma patient with COVID-19 infection receiving convalescent plasma
por: Karataş, Ayşe, et al.
Publicado: (2020)